Severe Influenza Cohort (ANTIGRIPPE)

Civil Hospices of Lyon

Status: Completed

Conditions: Severe Respiratory Infection; Influenza

Treatments: Other: influenza cohort

Study type: Interventional

Funder types: Other

Identifiers

NCT02392858

2014-A01023-44

Details and patient eligibility

About

Influenza is a major cause of morbidity and mortality. The investigators first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.

Enrollment: 227 patients

Sex: All

Ages: 1 month to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient (Adult or Pediatric)
• Hospitalized in reanimation
• With a laboratory confirmed Influenza
• That agree to take part in the study
• Affiliated to National Health Insurance

For ancillary group :

• Adult at least 60 years old
• Presenting at hospital for a blood test

Exclusion criteria

• non willing to participate
• Influenza infection with no respiratory symptoms
• pregnancy

For ancillary group :

• Presence of immunodepression defined by:

  • Cancer, or cancer cured for less than 2 years
  • Corticosteroids, Methotrexate (MTX), anti Tumor Necrosis Factor (TNF), anti-CD20

• Infection in progress (fever)

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

227 participants in 1 patient group

influenza cohort

Other group

Description:

Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. 1 control group of 30 patients (ancillary study) will be constitued to have reference values of the HLA-G5 marker. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.

Treatment:

Other: influenza cohort